No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Biotechnology
Hugel, Inc. is a biopharmaceutical firm headquartered in Chuncheon-si, South Korea, with a presence both domestically and internationally. The company specializes in the development and manufacturing of diverse medical solutions. A primary product is its Botulinum Toxin, presented as a clear glass vial containing a white, injectable dry powder. This therapeutic is prescribed for several conditions: treating essential eyelid spasms in adults over 18; ameliorating severe frown lines linked to corrugator and/or procerus muscle activity in adults aged 18 to 65; managing upper limb spasticity following a stroke; and correcting dynamic equinus foot deformity in children with cerebral palsy aged over 2. Furthermore, it aids in improving the lateral canthal lines (crow's feet) caused by orbicularis oculi muscle activity in adults between 19 and 65. This product is marketed under various labels, including Botulax, Regenox, Zentox, Reage, Magnion, Hugel Toxin, Juvenlife, Botulim, and Botoshot. Hugel also provides hyaluronic acid dermal fillers, known as Dermalax and The Chaeum; cosmetic products under the Wellage brand; and medical devices distributed as BlueRose. Hugel, Inc. commenced operations in 2001.
www.hugel-inc.comNo one on the platform currently holds 145020.KQ.
No tracked institution reports a position in 145020.KQ as of their last filing.
No one on the platform has traded 145020.KQ yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 19.3% | 14.9% | — | — | — | |
| Rev. Growth % | 14.0% | 15.0% | ||||
| Profit Margin % | 33.1% | 28.8% | ||||
| Free Cash Flow Margin % | 32.1% | 23.2% | ||||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $529.0B | +25.7% | $14036.06 | $12652.42–$15771.08 | — | 13 |
| 2027 | $635.0B | +20.0% | $17541.14 | $13248.81–$21365.69 | — | 15 |
| 2028 | $749.0B | +17.9% | $21400.33 | $18919.77–$23357.63 | — | 7 |
| 2029 | $947.0B | +26.4% | $0.00 | $0.00–$0.00 | — | 9 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 6 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-06 | $3018.81 | $3018.81 | +0.0% |
| 2026-05-07 | $2338.88 | $3136.20 | +34.1% |
| 2026-02-11 | $3516.22 | $3081.87 | -12.4% |
| 2025-11-04 | $3516.22 | $3269.04 | -7.0% |
| 2025-08-06 | $3293.16 | $3309.21 | +0.5% |
| 2025-05-08 | $2046.63 | $2640.06 | +29.0% |
| 2025-02-13 | $1902.51 | $3543.86 | +86.3% |
| 2024-11-06 | $2995.61 |
| $3570.00 |
| +19.2% |
| -0.15% |
| $447.8B |
| — |
| 226950.KQOliX Pharmaceuticals,Inc | $108300.00 | +8.19% | $2.20T | — |
| 302440.KSSK bioscience Co.,Ltd. | $36750.00 | -2.78% | $2.88T | — |
Source: Financial Modeling Prep · peers by sector/industry